Merck KGaA Signs Licensing Agreement with Abbisko for Pimicotinib
By Lalit Mishra
Pharma Deals Review: Vol 2023 Issue 12 (Table of Contents)
Published: 8 Dec-2023
DOI: 10.3833/pdr.v2023.i12.2842 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a significant move towards bolstering its oncology portfolio, Merck KGaA has entered into an exclusive license agreement with Abbisko Therapeutics for pimicotinib (ABSK021), a potent small molecule CSF-1R inhibitor currently in Phase III clinical trials for the treatment of tenosynovial giant cell tumour (TGCT)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS